Company: AEMD
Filing Date: 2025-09-05
Form Type: 424B4
Source: 0001683168-25-006701
Chunk: 10

Company: AETHLON MEDICAL INC
Filing Date: 2025-09-05
Form: 424B4
Chunk 10
---
-reviewed publication for review.

| 3 |

Platelet-derived extracellular
vesicles (PD-EVs) are the most numerous EV population in the body and are released by platelets in response to a variety of stimuli.
The cargo contained within these EVs have been noted to take part in damage to blood vessels, activation of immune cells and spread of
tumor cells. Excessive levels of PD-EVs have been implicated in a myriad of diseases including cancer, lupus, systemic sclerosis, multiple
sclerosis, Alzheimer’s disease, sepsis, acute and Long COVID.

We hypothesized that the Aethlon
Hemopurifier which contains a propriety GNA affinity resin would remove platelet derived EVs from plasma. In this experiment two hundred
milliliters on donated healthy human plasma were circulated over the Aethlon Hemoupurifier (HP) to simulate a clinical HP session. The
study results showed a 98.5% removal of platelet -derived EVs at a timepoint equivalent to a 4-hour HP treatment. The results of this
study support the current Australian Clinical Trial in Oncology as well as open the investigation of the Hemopurifier in many indications.

Extracellular vesicles have been
implicated in the pathogenesis of Long COVID. As we had previously demonstrated removal of extracellular vesicles by the Hemopurifier
in a patient with severe acute COVID-19 infection, we hypothesized that patients with Long COVID would have extracellular vesicles with
the mannose sugar on their surface that would bind to the affinity resin in our device. We partnered with investigators at the Univ of
California San Francisco Medical Center Long COVID clinic to obtain samples from participants with Long COVID as well as controls that
had had COVID -10 infection but had recovered. The data to be presented will review the binding of larger and smaller extracellular vesicles
to the GNA lectin and the lectin affinity resin, respectively. We believe the data from this pre-clinical study calls for additional
study of the Hemopurifier and look forward to receiving feedback from the Long COVID scientific community at the Keystone Symposium.

Successful outcomes of human
trials will also be required by the regulatory agencies of certain foreign countries where we plan to market and sell the Hemopurifier.
Some of our patents may expire before FDA approval or approval in a foreign country, if any, is obtained. However, we believe that certain
patent applications and/or other patents issued